Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, confirming compliance with key recommendations and detailing governance practices. This announcement underscores OncoSil’s commitment to transparency and regulatory compliance, potentially strengthening stakeholder confidence and supporting its market position.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd operates in the medical industry, focusing on the development and commercialization of medical devices for cancer treatment. The company’s primary product is the OncoSil device, which is designed to deliver targeted radiation therapy for pancreatic and liver cancer patients.
Average Trading Volume: 41,913
Technical Sentiment Signal: Sell
Current Market Cap: A$21.65M
Find detailed analytics on OSL stock on TipRanks’ Stock Analysis page.